Premium
PIII‐20
Author(s) -
Kim E.,
Shon J.,
Ryu J.,
Sunwoo Y.,
Jang J.,
Song K.,
Moon B.,
Joo S.,
Shin J.
Publication year - 2006
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2005.12.228
Subject(s) - luteinizing hormone , endocrinology , medicine , hormone , placebo , endocrine system , thyroid stimulating hormone , follicle stimulating hormone , crossover study , thyroid function , antagonist , receptor , alternative medicine , pathology
AIMS AND METHOD To evaluate the effect of revaprazan, novel gastric acid antagonist, on human endocrine functions, in randomized, double‐blind, crossover design, 200mg revaprazan or placebo were given orally to 13 male volunteers for 1 week with 2‐weeks washout. On the days before and after each treatment course, serum concentrations of tri‐iodothyronine (T 3 ), thyroxine (T 4 ), thyroid‐stimulating hormone (TSH), follicle‐stimulating hormone (FSH), and luteinizing hormone (LH) were measured, followed by TSH and LH response tests to thyrotropin releasing hormone (TRH) and luteinizing hormone releasing hormone (LHRH). RESULTS There were no differences in basal values for any hormone between placebo and revaprazan phases. For T 3 , T 4 , TSH, FSH, and LH, the geometric mean ratios (90% confidence interval) for placebo vs revaprazan were 1.04(0.996, 1.081), 1.00(0.947, 1.044), 1.27(0.973, 1.570), 0.92(0.833, 1.009), and 0.97(0.867, 1.075), respectively. The patterns of TSH‐LH response to TRH‐LHRH were not different between treatments (p>0.05, repeated‐measures ANOVA). CONCLUSION Revaprazan in clinical practice seems not to cause any significant interference in thyroid and gonadal function. Clinical Pharmacology & Therapeutics (2005) 79 , P63–P63; doi: 10.1016/j.clpt.2005.12.228